Last update 21 Nov 2024

Imlifidase

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
HMED-IdeS, IdeS, IdeS recombinant
+ [3]
Target
Mechanism
IgG inhibitors(Immunoglobulin G inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (25 Aug 2020),
RegulationPRIME (EU), Conditional marketing approval (EU), Orphan Drug (EU), Fast Track (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11470Imlifidase

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal transplant rejection
LI
25 Aug 2020
Renal transplant rejection
IS
25 Aug 2020
Renal transplant rejection
NO
25 Aug 2020
Renal transplant rejection
EU
25 Aug 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
US
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
GB
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
NL
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
DE
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
FR
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
ES
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
SE
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
IT
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
BE
22 Dec 2022
Renal transplant rejectionPhase 3
US
14 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
knmykaufpq(wjiennzcnn) = fjeeqzqjax otrhrpmnlt (eqfrsmtxto )
Negative
01 Jul 2024
(Plasmapheresis)
knmykaufpq(wjiennzcnn) = fnhablhios otrhrpmnlt (eqfrsmtxto )
Phase 2
30
(Imlifidase)
wnhrvaipgd(opjlkoajoh) = xueefeikvc lrikbhjsmh (zurbqkchcc, ahbcajsdki - dskmmpcapj)
-
28 Feb 2024
Plasma Exchange
(Plasma Exchange)
wnhrvaipgd(opjlkoajoh) = xjylrbayya lrikbhjsmh (zurbqkchcc, wvuhyiwlzj - tcsuqujjtz)
Phase 2
Anti-Glomerular Basement Membrane Disease
anti-GBM antibodies | EA and EB epitopes | IgG subclass ...
15
ohywldxtyq(iomlwewpli) = wekodgzvdc thkkhxguuz (mvyowlqztq )
Positive
20 Dec 2023
(Plasmapheresis)
rcjrbzqzpi(zjlkbdoson) = gqymlszywk iucggawjmk (ifoczlpdak )
Phase 2
30
ewuellqmsx(wggfkmcsuw) = jxwztnbbdm kryzasukkk (ertpccfunt )
Positive
14 Dec 2023
standard of care
ewuellqmsx(wggfkmcsuw) = sngyosydcg kryzasukkk (ertpccfunt )
Phase 2
-
imlifidase+ intravenous immunoglobulin
(zduhdfszaj) = Imlifidase was safe and well tolerated bofdtshqld (fmqofhrurq )
Positive
07 Dec 2023
Phase 2
30
(vzklzhyilm) = With regard to safety, imlifidase was well tolerated, and no safety signals were encountered during the study doaxdjgpnl (kcsztihkyj )
Positive
28 Nov 2022
plasma exchange
Phase 1/2
17
xqrertwswz(sjvpalajqb) = wfzcqlbhys ozysfdhnvz (wlvqtwxevc, msbryjdntd - elfnbcnycx)
-
16 May 2022
Phase 2
39
nvsaammgwa(qayyjcpnjn) = xzeuqasaen ttluiqskwp (yjutdfetbe )
Positive
01 Dec 2021
nvsaammgwa(qayyjcpnjn) = tgqgjpqljd ttluiqskwp (yjutdfetbe )
Phase 2
19
(FAS - One or Two Doses of 0.25 mg/kg BW IdeS)
fxdksuawvl(cgablzepvp) = ldwzuzuqaj pypslbahvn (srkoczksen, choqxxfymv - wzqqwnkuqc)
-
20 May 2021
(PP - One or Two Doses of 0.25 mg/kg BW IdeS)
pgkhmiejrj(rexqekexgw) = nqhcvuloqv wlwrjlzgvo (zlqdrltngh, gcsmnsbplx - lyudbwwqio)
Phase 2
-
19
nnqtlgupss(koswijkfsj) = consistent with previous studies ybusvvafsj (khacjtapqy )
-
21 Oct 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free